WebFeb 28, 2024 · The occurrence of cytopenias was not influenced by the efficacy and dose intensity of treating for ruxolitinib (Jakafi) in patients with steroid-refractory acute graft-vs-host disease (SR-aGVHD), according to a post hoc analysis of the REACH2 trial (NCT029132561) presented at the 2024 Transplantation & Cellular Therapy Meetings. WebJun 8, 2024 · The sNDA was based on data from REACH3, a Phase 3 randomized, open-label, multicenter study comparing ruxolitinib with best available therapy (BAT) in adult and pediatric patients 12 years and...
Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for …
WebApr 13, 2024 · REACH-2: Ruxolitinib Is Viable Option in Steroid-Refractory Acute GVHD Dingli Compares Trial Data and Recent ASH Updates in the Newly Diagnosed Multiple Myeloma … WebREACH3 is a phase 3 randomized trial that showed the superiority of ruxolitinib over common second-line therapeutic options, including … triangle copy and paste
Novartis announces data showing Jakavi® (ruxolitinib) more …
WebMar 19, 2024 · Recently, the FDA approved the use of ruxolitinib, a JAK1/2 inhibitor, in the treatment of acute steroid-refractory GVHD (SR-aGVHD), highlighting the role of JAK inhibition in this immune deregulation. Ruxolitinib was initially used to treat myelofibrosis and true polycythemia in a high-dose treatment and caused hematological toxicity. WebMethods: REACH-2 is a phase 3, randomized (1:1), open-label, multicenter study comparing ruxolitinib (10 mg twice daily) vs investigator-determined best available therapy (BAT) in patients with SR-aGvHD after allo-HSCT. Patients aged ≥ 12 years with clinically diagnosed grade II to IV SR-aGvHD with evidence of myeloid and platelet engraftment (absolute … WebSep 23, 2016 · Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell … tenplay ten news first